Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

From the articleFirst At-Home Thyroid Eye Disease Shot ApprovedAlso in Satralizumab Approved for Thyroid Eye Disease